James Carr assumes newly created marketing role at ARCA
James Carr is to head the marketing for a leading biopharma company involved in developing genetically targeted therapies for heart failure and other cardiovascular diseases.
James Carr is to head the marketing for a leading biopharma company involved in developing genetically targeted therapies for heart failure and other cardiovascular diseases.
Carr will define and execute marketing programmes to support ARCA Biopharmaceutical's lead product candidate Gencaro (bucindolol hydrochloride), a pharmacologically unique beta-blocker and mild vasodilator in late-stage development for heart failure. His role as vice president of marketing at the Broomfield-based business in Colorado has been newly created for him.
"Jim brings senior pharmaceutical industry experience and a deep knowledge of the heart failure market, which will be of significant value to ARCA as the company prepares to commercialise the first personalised cardiovascular medicine," said Richard B. Brewer, president and chief executive officer of ARCA.
Carr joins ARCA from Anesiva, Inc., where he served as vice president of marketing for pain management products since 2004.